Zynerba Pharmaceuticals, Inc.
Records under this name other than the patents Zynerba Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 16 patents it holds.
Showing 1 to 8 of 8 · Back to Zynerba Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,213,951 | Treatment of Autism with Cannabidiol Formerly held In force · High confidence | In force | High confidence | |
| US 12,226,373 | Treatment of Fragile X Syndrome with Cannabidiol Formerly held In force · Low confidence | In force | Low confidence | |
| US 12,186,282 | Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol Formerly held In force · High confidence | In force | High confidence | |
| US 12,508,270 | Treatment of Behavioral Impairment in Developmental and Epileptic Encephalopathy Formerly held In force · High confidence | In force | High confidence | |
| US 8,449,908 | Transdermal Delivery of Cannabidiol Term ended Term ended Mar 16, 2026 · Medium confidence | Term ended | Term ended Mar 16, 2026 | Medium confidence |
| US 8,481,560 | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists Formerly held Lapsed on the fee record Ended Jul 9, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 9, 2025 | From the USPTO record |
| US 8,435,556 | Transdermal Delivery of Cannabidiol Formerly held Term ended Term ended Jun 24, 2023 · Medium confidence | Term ended | Term ended Jun 24, 2023 | Medium confidence |
| US 9,533,942 | Use of cannabidiol prodrugs in topical and transdermal administration with microneedles Formerly held Surrendered on reissue Surrendered on reissue Mar 3, 2020 · From the USPTO record | Surrendered on reissue | Surrendered on reissue Mar 3, 2020 | From the USPTO record |